ResearchMoz

Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains

GBI Research
Published Date » 2013-10-31
No. Of Pages » N/A

GBI Research has released its research, “ Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains”, which provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan. It also covers disease epidemiology; treatment algorithms; treatment patterns; an in-depth analysis of clinical trials including failure rate analysis, pipeline analysis; and an analysis of deals relevant to macular degeneration. Apart from these the report also includes a heat map for the macular degeneration marketed products. 

GBI Research analysis shows that the APAC ophthalmology market for macular degeneration was valued at $675.7m in 2012. The market is expected to grow at a Compounded Annual Growth Rate (CAGR) of 6% for the forecast period and will reach $1,016m by 2019. Increase in the aging population and high annual cost of therapy of the marketed drugs are expected to drive the market valuations through 2019. However, the predominant off-label usage of Avastin for the treatment of the disease especially in developing countries like India and China act as a major barrier for growth of the market during the forecast period.

Scope

  • Disease overview along with treatment algorithms and treatment usage patterns
  • Market size and forecast for the macular degeneration market in APAC from 2012 to 2019
  • Major marketed products in the APAC along with a heat map
  • In-depth analysis of pipeline along with clinical trial failure analysis
  • Key drivers and restraints that have had a significant impact on the market
  • Key licensing and co-development agreements in the macular degeneration market

Reasons to Buy

  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the macular degeneration market
  • Develop key strategic initiatives by understanding the key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Macular Degeneration Asia-Pacific Market to 2019 – Introduction
2.1 Symptoms
2.2 Etiology
2.3 Pathophysiology
2.3.1 Disease Initiation
2.3.2 Disease Propagation
2.4 Classification
2.4.1 Early AMD
2.4.2 Intermediate AMD
2.4.3 Advanced AMD
2.5 Co-morbidities and Complications
2.6 Diagnosis
2.6.1 History
2.6.2 Examination
2.6.3 Diagnostic Tests
2.7 Epidemiology
2.8 Prognosis and Disease Staging
2.9 Treatment Options
2.9.1 Pharmacological
2.9.2 Treatment Algorithms and Prescribing Habits
2.9.3 Non-pharmacological Care

3 Macular Degeneration Asia-Pacific Market to 2019 – Marketed Products
3.1 Therapeutic Landscape
3.1.1 Lucentis (ranibizumab) – Novartis AG/Roche (Genentech)
3.1.2 Eylea (aflibercept) – Regeneron Pharmaceuticals/Bayer Healthcare
3.1.3 Avastin (bevacizumab) – Genentech (Roche)
3.1.4 Macugen (pegaptanib sodium) – Valeant Pharmaceuticals/Pfizer
3.1.5 Visudyne (verteporfin injection) – Novartis AG
3.1.6 Triamcinolone Acetonide
3.2 Comparative Efficacy and Safety

4 Macular Degeneration Asia-Pacific Market to 2019 – Pipeline for Disease
4.1 Overall Pipeline
4.2 Pipeline Analysis by Molecule Type
4.3 Pipeline Analysis by Mechanism of Action
4.4 Clinical Trials
4.4.1 Failure Rate
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.5 Promising Drug Candidates in the Pipeline
4.5.1 MC-1101 – MacuCLEAR, Inc.
4.5.2 KH902 (Fumintide) – Chengdu Kanghong Pharmaceuticals Group Co., Ltd.

5 Macular Degeneration Asia-Pacific Market to 2019 – Market Forecast to 2019
5.1 Geographical Markets
5.1.1 APAC Market
5.1.2 Australia
5.1.3 China
5.1.4 India
5.1.5 Japan
5.2 Drivers and Barriers for the Disease Market
5.2.1 Drivers
5.2.2 Barriers

6 Macular Degeneration Asia-Pacific Market to 2019 – Deals and Strategic Consolidations
6.1 Deals Analysis
6.2 Major Co-development Deals
6.2.1 Sinphar Enters into Co-development Agreement with MacuCLEAR
6.2.2 Allergan Enters into Co-development Agreement with Molecular Partners
6.2.3 X-Body BioSciences Enters into Co-development Agreement with Hengrui Medicine for AMD
6.2.4 Alcon Enters into Collaboration with AstraZeneca
6.2.5 Acucela Enters into Co-Development Agreement with Otsuka Pharma for ACU-4429
6.3 Major Licensing Deals
6.3.1 Allegro Ophthalmics Enters into Licensing Agreement with Senju Pharma to Develop Integrin Peptide Therapy
6.3.2 Allergan Enters into Licensing Agreement with Molecular Partners
6.3.3 PanOptica Enters into Licensing Agreement with OSI Pharma
6.3.4 Lpath Enters into Licensing Agreement with Pfizer
6.3.5 Shionogi Enters into Licensing Agreement with OncoTherapy Science

7 Macular Degeneration Asia-Pacific Market to 2019 – Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND-filed and Phase 0
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.1.7 Undisclosed
7.2 Market Forecasts to 2019
7.2.1 Asia-Pacific
7.2.2 Australia
7.2.3 China
7.2.4 India
7.2.5 Japan
7.3 Market Definitions
7.4 Abbreviations
7.5 References
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer

List of Tables


Table 1: Macular Degeneration Market, Classification of AMD
Table 2: Macular Degeneration Market, Treatment Recommendations and Follow-up for Non-neovascular AMD
Table 3: Macular Degeneration Market, Treatment Recommendations and Follow-up for Neovascular AMD
Table 4: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Discovery), 2013
Table 5: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Preclinical), 2013
Table 6: Macular Degeneration Market, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013
Table 7: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase I), 2013
Table 8: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase II), 2013
Table 9: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 10: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013
Table 11: Macular Degeneration Market, Asia-Pacific, Market Forecast, 2012–2019
Table 12: Macular Degeneration Market, Australia, Market Forecast, 2012–2019
Table 13: Macular Degeneration Market, China, Market Forecast, 2012–2019
Table 14: Macular Degeneration Market, India, Market Forecast, 2012–2019
Table 15: Macular Degeneration Market, Japan, Market Forecast, 2012–2019

List of Figures


Figure 1: Macular Degeneration Market, Pathophysiology of AMD
Figure 2: Macular Degeneration Market, Types of Dry AMD
Figure 3: Macular Degeneration Market, Classification of AMD
Figure 4: Macular Degeneration Market, Amsler Grid Test
Figure 5: Macular Degeneration Market, Asia-Pacific, Epidemiology, 2012–2019
Figure 6: Macular Degeneration Market, Photodynamic Therapy
Figure 7: Macular Degeneration Market, Treatment Algorithm by Type and by Stage
Figure 8: Macular Degeneration Market, Fluorescein Angiogram Showing Laser Photocoagulation Images
Figure 9: Macular Degeneration Market, Global, Annual Sales ($m), 2012
Figure 10: Macular Degeneration Market, Lucentis, Global, Annual Sales ($m), 2006–2012
Figure 11: Macular Degeneration Market, Eylea, Global, Annual Sales ($m), 2011–2012
Figure 12: Macular Degeneration Market, Visudyne, Global, Annual Sales ($m), 2005–2012
Figure 13: Macular Degeneration, Global, Heat Map of Safety and Efficacy for Marketed Products
Figure 14: Macular Degeneration Market, Global, Pipeline, 2013
Figure 15: Macular Degeneration Market, Global, Pipeline, 2013
Figure 16: Macular Degeneration Market, Global, Pipeline, 2013
Figure 17: Macular Degeneration Market, Global, Clinical Trial Failure Rate, 2013
Figure 18: Macular Degeneration Market, Global, Pipeline, Clinical Trial Duration, 2013
Figure 19: Macular Degeneration Market, Global, Pipeline, Clinical Trial Size, 2013
Figure 20: Macular Degeneration Market, Global, Annual Sales ($bn), 2012–2019
Figure 21: Macular Degeneration Market, Australia, Annual Sales ($m), 2012–2019
Figure 22: Macular Degeneration Market, China, Annual Sales ($m), 2012–2019
Figure 23: Macular Degeneration Market, India, Annual Sales ($m), 2012–2019
Figure 24: Macular Degeneration Market, Japan, Annual Sales ($m), 2012–2019
Figure 25: Macular Degeneration Market, Global, Deals, 2007–2013
Figure 26: Macular Degeneration Market, Global, Co-development Deals, 2007–2013
Figure 27: Macular Degeneration Market, Global, Licensing Deals, 2007–2013
Figure 28: GBI Research Market Forecasting Model

Upcoming Reports:

Uterine Cancer Therapies and Diagnostic Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Uterine cancer is a cancer of uterus and is classified into the following four types, namely uterine sarcomas, endometrial cancer, cervical cancer and gestational trophoblastic disease. These cancers arise from malignancies of connective tissues, endometrium and cervix uteri of the uterus. Uterine cancers are the fourth most common cancers among women overall. According to American Cancer Society (ACS), uterine sarcoma accounts for 5% of the total global uterine cancer cases whereas endometrial cancer is most prevalent form of uterine cancer.  Both of these cancers can be...
Polymethyl Methacrylate (PMMA) Market - Global Industry Size, Market Share, Trends, Analysis And Forecast, 2012 - 2018
By - Transparency Market Research
Polymethyl methacrylate, abbreviated as PMMA, is a clear transparent thermoplastic, used as a substitute of glass. The fragility of glass has seen increased adoption of PMMA across various industries, which find the impact resistant, chemical resistant and weather resistant properties of PMMA significantly important. Demand for PMMA across industries such as electronics, signs and display, lighting fixtures, automotive, construction, and sanityware has induced a sharp growth trend in the global PMMA market, especially after the recession of 2009. The global PPMA market, which...
Membrane Separation Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Membrane Separation is a technology used to separate materials via pores or minute gap in the molecular arrangement without adding any chemicals. Major membrane processes used for water treatment are microfiltration, ultrafiltration, nanofiltration and reverse osmosis. Membrane Separation is majorly used for desalination of seawater, process water (used for industrial processes and building systems) from groundwater, surface water or wastewater and demineralization of boiler feed water. Pharmaceutical, life sciences, food and beverages industry and biopharmaceutical industry are the other...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...
Infrared Sensors can Soon Be Used to Develop Night-Vision Lenses - A New Discovery Confirms
Apr 8, 2014  
People who fear the dark may soon have a reason to rejoice – an infrared sensor that can eventually be used for mechanizing night-vision lenses has been developed. This effectively means that one can also see through dark with the help of these lenses.  This technology seems possible all due to graphene, a layer of tightly packed carbon atoms that has allowed the creation of...
Ontarios thanks Sustainable Development Technology Canada for Clean Tech Ecosystem Movements
Apr 8, 2014  
Sustainable Development Technology Canada has leveraged an extra $2.2 billion in funding from project partners that also includes global clean technology companies.  Sustainable Development Technology Canada (SDTC) is energizing and evolving the development and demonstration of a clean technology ecosystem. They are the vital contributors to the prominent concentration of clean...